食管癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT03801876 / NCI-2018-03378

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

AI 简述这是一项III期试验，比较质子治疗与光子放疗用于食管癌。在美国开展。

?

适用疾病: Stage I Esophageal Adenocarcinoma；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: NRG Oncology

正在招募 Phase 3

NCI NCT04157985 / NCI-2020-02016

Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors

AI 简述这是一项III期试验，比较免疫治疗不同治疗时长用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 3

NCI NCT05677490 / NCI-2022-08569

mFOLFIRINOX versus mFOLFOX with or without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

AI 简述这是一项III期试验，比较mFOLFIRINOX与mFOLFOX联合或不联合Nivolumab用于晚期HER2阴性食管癌、胃食管结合部癌和胃癌。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 2, Phase 3

NCI NCT06203600 / NCI-2023-11064

Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

AI 简述这是一项II/III期试验，在晚期胃癌或食管癌中加用Nivolumab。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: SWOG

正在招募 Phase 3

NCI NCT06265285 / NCI-2024-00637

Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

AI 简述这是一项III期试验，比较Nivolumab在家与在诊所给药用于多种癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 2, Phase 3

NCI NCT06367972 / NCI-2024-03278

Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial

AI 简述这是一项II/III期试验，研究局部巩固治疗联合系统治疗用于寡进展转移性癌症，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 3

NCI NCT06764875 / NCI-2025-03123

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AI 简述这是一项III期试验，研究Rilvegostomig联合氟嘧啶和Trastuzumab Deruxtecan用于一线治疗HER2阳性胃癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 3

NCI NCT06901531 / NCI-2025-03502

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

AI 简述这是一项III期试验，研究Zolbetuximab联合Pembrolizumab和化疗用于局部晚期不可切除或转移性胃及胃食管结合部腺癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 3

NCI NCT06731478 / NCI-2025-07299

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

AI 简述这是一项III期试验，研究Trastuzumab Deruxtecan联合帕博利珠单抗、曲妥珠单抗和化疗用于HER2阳性胃或胃食管结合部癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 3

NCI NCT07043400 / NCI-2025-07441

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项III期试验，比较替雷利珠单抗皮下注射与静脉输注联合化疗用于不可切除或转移性胃或胃食管结合部腺癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: BeOne Medicines

正在招募 Phase 3 放疗

ClinicalTrials.gov NCT04328948

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC

AI 简述这是一项III期试验，在日本开展，研究预防性照射在放化疗中对cT1bN0M0食管鳞癌的作用。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Chemoradiotherapy
地点: Japan
申办方: National Cancer Center, Japan

正在招募 Phase 3 药物手术/操作放疗

ClinicalTrials.gov NCT04460352

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

AI 简述这是一项III期试验，比较放化疗后计划手术与仅必要时手术用于食管鳞癌，在加拿大等地开展。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Neoadjuvant radiotherapy (arm A)，Carboplatin, paclitaxel，Esophagectomy，Neoadjuvant radiotherapy (arm B)
地点: Canada，Ireland，Norway，Sweden 等 1 个
申办方: Karolinska University Hospital

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

AI 简述这是一项III期试验，比较标准免疫治疗与每3个月给药一次的方案用于多种癌症。

?

适用疾病: Lung Cancer Metastatic；Renal Cell Carcinoma；Head and Neck Cancer
干预: Reduced dose intensity of IO
地点: France
申办方: UNICANCER

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05188313

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

AI 简述这是一项III期试验，研究Trastuzumab和Pertuzumab联合化疗用于HER2阳性可切除食管癌。

?

适用疾病: Esophageal Cancer；Esophageal Adenocarcinoma
干预: Trastuzumab，Pertuzumab，Paclitaxel，Carboplatin
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 3 手术/操作

ClinicalTrials.gov NCT05547529

The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer

AI 简述一项III期试验，比较新辅助放化疗与新辅助化疗用于可切除食管鳞癌（俄罗斯）。

?

适用疾病: Esophageal Cancer
干预: Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.，Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
地点: Russia
申办方: Blokhin's Russian Cancer Research Center

正在招募 Phase 2, Phase 3 药物手术/操作放疗

ClinicalTrials.gov NCT07000253

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

AI 简述这是一项II/III期试验，在荷兰研究一线系统治疗后局部治疗时机用于寡转移食管或胃腺癌。

?

适用疾病: Esophageal Cancer；Gastric (Stomach) Cancer；Gastric Adenocarcinoma
干预: Chemotherapy，Targeted Systemic Therapy，Immunotherapy，Surgery
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 2

NCI NCT01573468 / NCI-2012-00660

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

AI 简述这是一项II期试验，比较Tesetaxel联合卡培他滨与安慰剂联合卡培他滨用于胃癌或食管癌。

?

适用疾病: Recurrent Esophageal Cancer；Esophageal Adenocarcinoma；Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Genta Inc

正在招募 Phase 2

NCI NCT01174121 / NCI-2019-00142

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

AI 简述这是一项II期试验，研究肿瘤浸润淋巴细胞联合Pembrolizumab用于转移性癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT03935893 / NCI-2019-06773

Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers

AI 简述这是一项II期试验，研究细胞疗法用于局部晚期、转移性或复发性实体瘤，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT04145622 / NCI-2020-03139

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

AI 简述这是一项I/II期试验，研究Ifinatamab Deruxtecan用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 2

NCI NCT04069273 / NCI-2020-06409

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

AI 简述这是一项II期试验，研究派姆单抗联合雷莫西尤单抗和紫杉醇用于晚期胃食管腺癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Harry H Yoon

正在招募 Phase 2

NCI NCT04379596 / NCI-2020-10070

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

AI 简述这是一项II期试验，研究T-DXd联合方案用于HER2阳性晚期胃癌，在中国等多国开展。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2

NCI NCT04771520 / NCI-2021-00702

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

AI 简述这是一项II期试验，研究Avapritinib用于CKIT或PDGFRA突变阳性晚期实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04895709 / NCI-2021-06088

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986340单药或联合治疗用于晚期实体瘤，包括宫颈癌、肺癌等。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2

NCI NCT04787042 / NCI-2021-09248

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

AI 简述这是一项I/II期试验，研究ST-067用于实体瘤、黑色素瘤、肾细胞癌和三阴性乳腺癌，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Metastatic Urothelial Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Simcha IL-18, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05269381 / NCI-2022-01258

Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study

AI 简述这是一项I/II期试验，研究新抗原肽疫苗联合Pembrolizumab用于晚期实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 2

NCI NCT05332002 / NCI-2022-02448

Combination Chemotherapy for the Treatment of Metastatic or Unresectable Gastroesophageal Cancers, SAGE Trial

AI 简述这是一项2期试验，研究sFOLFOXIRI用于晚期胃食管癌，在美国开展。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Rutgers Cancer Institute of New Jersey

正在招募 Phase 1, Phase 2

NCI NCT04723810 / NCI-2022-03872

Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care

AI 简述这是一项I/II期试验，研究吲哚青绿用于实体瘤术中成像，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Sarcoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05358379 / NCI-2022-04029

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CYC140用于晚期实体瘤和淋巴瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05101070 / NCI-2022-06439

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究S-531011单药及联合免疫检查点抑制剂用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Shionogi

正在招募 Phase 2

NCI NCT05453825 / NCI-2022-07031

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

AI 简述这是一项II期试验，研究Navicixizumab单药或联合用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: OncXerna Theraputics, Inc.

正在招募 Phase 2

NCI NCT05651594 / NCI-2022-09209

Propranolol in Combination with Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项II期试验，普萘洛尔联合帕博利珠单抗和标准化疗用于不可切除局部晚期或转移性食管或胃食管结合部腺癌。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05482893 / NCI-2022-10638

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

AI 简述这是一项1/2期试验，研究Spevatamig单药或联合化疗用于晚期胃腺癌、胰腺癌等，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Phanes Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT05584670 / NCI-2023-00867

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，首次人体研究SAR445877用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sanofi Aventis

正在招募 Phase 2

NCI NCT05969860 / NCI-2023-05420

At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls

AI 简述这是一项II期试验，比较在家与在医院进行癌症治疗用于晚期癌症患者。

?

适用疾病: Advanced Malignant Solid Tumor；Advanced Head and Neck Cancer；Advanced Melanoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 1, Phase 2

NCI NCT05934539 / NCI-2023-05619

ALG.APV-527 First-in-human Study

AI 简述这是一项I/II期试验，研究ALG.APV-527用于转移性尿路上皮癌及晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Aptevo Therapeutics

正在招募 Phase 2

NCI NCT05977998 / NCI-2023-05915

Perioperative Intraperitoneal Paclitaxel for the Treatment of Stage IV Gastric or Gastroesophageal Adenocarcinoma with Carcinomatosis or Positive Cytology

AI 简述这是一项II期试验，研究围手术期紫杉醇用于胃腺癌伴腹膜转移或腹腔细胞学阳性。

?

适用疾病: Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer；Metastatic Gastroesophageal Junction Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06078709 / NCI-2023-07432

Preoperative Hypofractionated Radiotherapy with FOLFOX for the Treatment of Stage I-III Esophageal or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项II期试验，研究术前的低分次放疗联合FOLFOX用于I-III期食管或胃食管结合部腺癌。

?

适用疾病: Stage I Esophageal Adenocarcinoma；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1, Phase 2

NCI NCT05902988 / NCI-2023-08591

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

AI 简述这是一项I/II期试验，研究VLS-1488用于晚期实体瘤，包括卵巢癌、肺癌、乳腺癌等，在美国开展。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer
干预: 未列出
地点: United States
申办方: Volastra Therapeutics, Inc.

正在招募 Phase 2

NCI NCT06038578 / NCI-2023-09551

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

AI 简述这是一项II期试验，研究TRK-950联合Ramucirumab和Paclitaxel用于胃癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Toray Industries, Inc

正在招募 Phase 1, Phase 2

NCI NCT05914116 / NCI-2024-01206

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/IIa期试验，在美国研究DB-1311/BNT324用于晚期/转移性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 2

NCI NCT06123338 / NCI-2024-01388

Pembrolizumab with Trastuzumab and Chemotherapy for the Treatment Resectable HER2-Positive Gastric, Esophageal, and Gastroesophageal Junction Cancer

AI 简述这是一项II期试验，研究帕博利珠单抗联合曲妥珠单抗和化疗用于可切除HER2阳性胃食管结合部癌，在美国开展。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IVA Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2

NCI NCT06219941 / NCI-2024-05381

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

AI 简述这是一项II期试验，研究AZD0901用于表达Claudin18.2的晚期实体瘤，在多个国家包括中国开展。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 1, Phase 2

NCI NCT06596694 / NCI-2025-00174

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

AI 简述这是一项I/II期试验，研究Patritumab Deruxtecan用于胃肠道癌症，在美国开展。

?

适用疾病: Unresectable Esophageal Carcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 2

NCI NCT06330064 / NCI-2025-00431

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

AI 简述这是一项II期试验，研究Ifinatamab deruxtecan用于复发或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Metastatic Malignant Solid Tumor；Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 2

NCI NCT06695845 / NCI-2025-02546

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

AI 简述这是一项2期试验，研究Zanidatamab用于HER2表达肿瘤，在美国、韩国、西班牙等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Jazz Pharmaceuticals

正在招募 Phase 2

NCI NCT05702229 / NCI-2025-04132

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项II期试验，在美国、中国等地研究新型组合用于局部晚期或转移性胃癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2

NCI NCT07139951 / NCI-2025-05845

Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Paclitaxel for the Treatment of Patients with Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence, HORIZON Trial

AI 简述这是一项II期试验，研究腹腔热灌注化疗联合顺铂和紫杉醇用于高腹膜复发风险的胃癌及胃食管结合部腺癌。

?

适用疾病: Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1, Phase 2

NCI NCT07070232 / NCI-2025-06009

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

AI 简述这是一项I/II期试验，研究BNT326联合BNT327用于晚期恶性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 1, Phase 2

NCI NCT06921928 / NCI-2025-06174

Study for AZD4360 in Participants With Advanced Solid Tumours

AI 简述这是一项I/II期试验，研究AZD4360用于晚期实体瘤，包括胃癌、胆道癌等。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 1, Phase 2

NCI NCT07124117 / NCI-2025-07305

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究OBI-902用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: OBI Pharma, Inc

正在招募 Phase 1, Phase 2

NCI NCT07197827 / NCI-2025-07559

A Study of YL242 in Subjects With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究YL242用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 2

NCI NCT07070466 / NCI-2025-07695

Ivonescimab in Combination with a Standard Chemotherapy Regimen (FOLFOX) for Controlling Disease Progression in Patients with HER2 Negative Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项II期试验，研究Ivonescimab联合FOLFOX用于晚期HER2阴性胃食管腺癌。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07205718 / NCI-2025-08225

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

AI 简述这是一项I/II期试验，研究TAK-188用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage III Lip and Oral Cavity Cancer
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 1, Phase 2

NCI NCT07115043 / NCI-2025-09704

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究AZD6750联合rilvegostomig用于多种晚期实体瘤。在美国、澳大利亚、日本、韩国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2

NCI NCT07069712 / NCI-2026-00125

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

AI 简述这是一项II期试验，研究多种新药用于可切除胃食管腺癌围手术期治疗。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 1, Phase 2

NCI NCT07287995 / NCI-2026-02678

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

AI 简述这是一项I/II期试验，研究ASP2998单用及联合标准疗法用于实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT07186842 / NCI-2026-03238

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

AI 简述这是一项I/II期试验，研究BNT329用于晚期实体瘤（表达CA19-9）。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 1, Phase 2

NCI NCT07335497 / NCI-2026-03444

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究CR-001用于局部晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Crescent Biopharma, Inc.

正在招募 Phase 2

NCI NCT07475286 / NCI-2026-04624

Combined Systemic and Intraperitoneal Chemotherapy for the Treatment of Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

AI 简述这是一项II期试验，研究全身联合腹腔化疗用于胃及胃食管连接处腹膜癌病。

?

适用疾病: Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer；Metastatic Gastroesophageal Junction Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 2

NCI NCT07631000 / NCI-2026-04628

A Study of Cadonilimab Combined with Chemotherapy in Treating Patients with Gastric or Gastroesophageal Junction Cancer

AI 简述这是一项II期试验，在美国研究Cadonilimab联合化疗用于胃癌或胃食管交界处癌。

?

适用疾病: Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT03161522 / NCI-2018-01202

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

AI 简述这是一项II期试验，研究化疗联合或不联合放疗或手术用于寡转移食管癌或胃癌，在美国开展。

?

适用疾病: Gastric Adenocarcinoma；Oligometastasis；Stage IV Esophageal Adenocarcinoma AJCC v7
干预: Capecitabine，Chemotherapy，Conventional Surgery，Fluorouracil
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov / NCI NCT03526835 / NCI-2021-03548

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究双特异性抗体MCLA-158用于晚期实体瘤。在美国、比利时、法国、荷兰等开展。

?

适用疾病: Advanced/Metastatic Solid Tumors；Colorectal Cancer；Gastric Cancer
干预: MCLA-158，MCLA-158 + Pembrolizumab，MCLA-158 + FOLFIRI，MCLA-158 + FOLFOX
地点: United States，Belgium，France，Netherlands 等 2 个
申办方: Merus B.V.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03539822 / NCI-2019-00380

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

AI 简述这是一项I/II期试验，研究Cabozantinib联合Durvalumab加或不加Tremelimumab用于胃癌、食管腺癌等消化道肿瘤。

?

适用疾病: Gastric Cancer；Esophageal Adenocarcinoma；Hepatocellular Carcinoma
干预: Cabozantinib，Durvalumab，Tremelimumab
地点: United States
申办方: Anwaar Saeed

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03556228 / NCI-2018-01333

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

AI 简述这是一项I/II期试验，研究VMD-928单药或联合Pembrolizumab用于TrkA过表达的实体瘤或淋巴瘤。

?

适用疾病: Head and Neck Carcinoma；Adenoid Cystic Carcinoma；Lung Cancer
干预: VMD-928 100 mg Tablet，VMD-928 Tablet and Pembrolizumab (200 mg)
地点: United States，Puerto Rico
申办方: VM Oncology, LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04018872

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

AI 简述这是一项II期试验，研究伊曲康唑用于食管癌。

?

适用疾病: Esophagus Adenocarcinoma；Esophagus Squamous Cell Carcinoma；Gastroesophageal Junction Adenocarcinoma
干预: Itraconazole
地点: United States
申办方: Dallas VA Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04114136 / NCI-2020-11521

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

AI 简述这是一项II期试验，研究PD-1抑制剂联合二甲双胍、罗格列酮用于多种实体瘤。

?

适用疾病: Melanoma；NSCLC；Hepatocellular Carcinoma
干预: Nivolumab or Pembrolizumab (dependent upon approved indication)，Metformin，Rosiglitazone
地点: United States
申办方: Dan Zandberg

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04150640 / NCI-2019-07966

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

AI 简述这是一项II期试验，研究Nal-IRI和奥沙利铂联合曲妥珠单抗（用于HER2阳性）治疗晚期食管和胃腺癌。

?

适用疾病: Esophageal Adenocarcinoma；Gastric Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: Nal-IRI，Oxaliplatin，5-FU，Trastuzumab
地点: United States
申办方: University of Wisconsin, Madison

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT04656041

Folfox+Irinotecan+Chemort In Esophageal Cancer

AI 简述这是一项II期试验，研究FOLFOX/nal-IRI联合化疗和质子放疗用于食管胃结合部腺癌。

?

适用疾病: Gastroesophageal Junction Adenocarcinoma；Esophagogastric Cancer
干预: FOLFOX/ nal-IRI，Paclitaxel，Carboplatin，Proton Radiation Therapy
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT04682158 / NCI-2020-13873

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

AI 简述这是一项II期试验，研究普萘洛尔联合标准放化疗用于食管腺癌。

?

适用疾病: Esophageal Adenocarcinoma
干预: Carboplatin，3 Dimensional Conformal Radiation Therapy，Propranolol，Intensity Modulated Radiation Therapy
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05086692 / NCI-2022-02678

A Beta-only IL-2 ImmunoTherapY Study

AI 简述这是一项I/II期试验，研究MDNA11联合Pembrolizumab用于晚期实体瘤，在美、澳、加、爱等地开展。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Clear Cell Renal Cell Carcinoma
干预: MDNA11，Pembrolizumab (KEYTRUDA®)
地点: United States，Australia，Canada，Ireland 等 3 个
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT05144698

RAPA-201 Therapy of Solid Tumors

AI 简述这是一项I/II期试验，研究RAPA-201用于多种实体瘤。

?

适用疾病: Solid Tumor；Small Cell and Non-small Cell Lung Cancer；Head and Neck Cancer
干预: RAPA-201 Rapamycin Resistant T Cells，Chemotherapy Prior to RAPA-201 Therapy，Pembrolizumab (PD-1 Blocking Antibody)
地点: United States
申办方: Rapa Therapeutics LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05177133

Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)

AI 简述这是一项II期试验，研究Retifanlimab联合Capecitabine和Oxaliplatin用于dMMR食管胃癌，在荷兰开展。

?

适用疾病: Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: Capecitabine，Oxaliplatin，Retifanlimab
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05183126

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

AI 简述这是一项IV期试验，研究基于骨骼肌面积的紫杉醇输注药代动力学，用于乳腺癌、转移性胃癌、食管癌患者，在美国开展。

?

适用疾病: Breast Cancer；Metastatic Gastric Cancer；Esophageal Cancer
干预: Paclitaxel，Paclitaxel
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05473156

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

AI 简述这是一项I/II期试验，研究AP203用于局部晚期或转移性实体瘤。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；Non Small Cell Lung Cancer (NSCLC)；Head and Neck Squamous Cell Carcinoma (HNSCC)
干预: AP203，AP203
地点: Taiwan
申办方: AP Biosciences Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05476796

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

AI 简述这是一项2期试验，研究奥沙利铂联合纳武利尤单抗及化疗用于虚弱晚期胃癌、食管癌或胃食管结合部癌，在法国开展。

?

适用疾病: Gastric Adenocarcinoma；Esophagus Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: Trifluridine/Tipiracil，Oxaliplatin，FOLFOX regimen，Nivolumab
地点: France
申办方: UNICANCER

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05563766

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

AI 简述这是一项II期试验，研究伊曲康唑用于可切除食管癌。

?

适用疾病: Esophageal Adenocarcinoma；Esophageal Squamous Cell Carcinoma；Gastroesophageal Junction Carcinoma
干预: Itraconazole
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05910827

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

AI 简述这是一项I/II期试验，在澳洲等地研究HMBD-001联合Cetuximab±Docetaxel用于晚期鳞状细胞癌。

?

适用疾病: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer；Advanced Head and Neck Squamous Cell Carcinoma；Advanced Esophageal Squamous Cell Carcinoma
干预: HMBD-001，Docetaxel，Cetuximab
地点: Australia，Moldova，Singapore，South Korea 等 1 个
申办方: Hummingbird Bioscience

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05944237

HTL0039732 in Participants With Advanced Solid Tumours

AI 简述这是一项1/2期试验，研究HTL0039732用于晚期实体瘤，在英国等地开展。

?

适用疾病: Neoplasms；Prostatic Neoplasms, Castration-Resistant；Stomach Neoplasms
干预: HTL0039732 Capsules，HTL0039732 Capsules and atezolizumab infusion
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05965479

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

AI 简述这是一项II期试验，研究Trastuzumab deruxtecan用于ctDNA指导的胃食管癌辅助治疗。在英国开展。

?

适用疾病: Gastrooesophageal Cancer
干预: Trastuzumab deruxtecan
地点: United Kingdom
申办方: University of Southampton

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06047379 / NCI-2024-08760

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

AI 简述这是一项1/2期试验，研究NEO212用于星形细胞瘤、胶质母细胞瘤或脑转移瘤。在美国开展。

?

适用疾病: Diffuse Astrocytoma, IDH-Mutant；Glioblastoma, IDH-wildtype；Brain Metastases, Adult
干预: NEO212 Oral Capsule，Ipilimumab，Pembrolizumab，Nivolumab
地点: United States
申办方: Neonc Technologies, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06161818

Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

AI 简述这是一项II期试验，研究FLOT-CROSS方案用于淋巴结阳性食管腺癌。

?

适用疾病: Esophageal Cancer；Adenocarcinoma of the Esophagus
干预: FLOT-CROSS or CROSS-FLOT
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06250036

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

AI 简述这是一项II期试验，研究Zimberelimab单药或联合Domvanalimab用于可切除的dMMR胃癌或胃食管结合部癌，在英国开展。

?

适用疾病: Locally Advanced Gastric Adenocarcinoma；MSI-H/dMMR Gastric Cancer；MSI-H/dMMR Gastroesophageal-junction Cancer
干预: Single agent zimberelimab，Combination zimberelimab + domvanalimab
地点: United Kingdom
申办方: Royal Marsden NHS Foundation Trust

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06329869

Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，研究Sacituzumab govitecan用于晚期食管鳞状细胞癌。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Sacituzumab govitecan
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06340711 / NCI-2026-02016

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

AI 简述这是一项II期试验，研究Suratadenoturev联合帕博利珠单抗用于食管胃腺癌，在美国开展。

?

适用疾病: Esophageal Adenocarcinoma；Gastric Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: OBP-301，Pembrolizumab
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06380816

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

AI 简述这是一项I/II期试验，在UK研究UCB4594用于晚期实体瘤，包括头颈鳞癌、非小细胞肺癌等。

?

适用疾病: Advanced Solid Tumours；Squamous Cell Carcinoma of Head and Neck；Carcinoma, Non-Small-Cell Lung
干预: UCB4594
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

AI 简述这是一项II期试验，研究减少免疫检查点抑制剂给药频率用于晚期癌症。在新加坡开展。

?

适用疾病: Carcinoma, Hepatocellular；Gastric Adenocarcinoma；GastroEsophageal Cancer
干预: Extended Dosing Interval - A，Extended Dosing Interval - B，Extended Dosing Interval - C，Standard of Care - A
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 4 药物手术/操作

ClinicalTrials.gov NCT06594744

Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC

AI 简述这是一项IV期试验，比较内镜下食管静脉曲张结扎术与卡维地洛用于预防肝癌患者首次食管静脉曲张出血，在台湾开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Esophageal Varices
干预: Endoscopic variceal ligation，Carvedilol
地点: Taiwan
申办方: Taipei Veterans General Hospital, Taiwan

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06687876

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

AI 简述这是一项II期试验，研究二甲双胍用于食管腺癌新辅助放化疗的代谢干预，在荷兰开展。

?

适用疾病: Oesophageal Adenocarcinoma；Tumor Microenvironment
干预: Metformin
地点: Netherlands
申办方: Amsterdam UMC, location VUmc

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

AI 简述这是一项I/II期试验，研究[212Pb]Pb-PSV359治疗用于胰腺癌、胃癌、食管癌等实体瘤。在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Gastric Cancer；Esophageal Cancer
干预: [203Pb]Pb-PSV359，[212Pb]Pb-PSV359
地点: United States
申办方: Perspective Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06747585 / NCI-2025-03675

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

AI 简述这是一项I/II期试验，研究ALE.P02用于CLDN1阳性实体瘤，在美国、法国等地开展。

?

适用疾病: Squamous Non-small-cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Cervical Squamous Cell Carcinoma
干预: ALE.P02
地点: United States，France，Hong Kong，Italy 等 4 个
申办方: Alentis Therapeutics AG

正在招募 Phase 2 手术/操作

ClinicalTrials.gov NCT06819566

Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC

AI 简述这是一项II期试验，在韩国开展，研究内镜下食管静脉曲张套扎术用于接受Atezo/Bev治疗的肝细胞癌伴高危食管静脉曲张患者。

?

适用疾病: Hepatocellular Carcinoma；Esophageal Varix；Bleeding Esophageal Varices
干预: Endoscopic variceal ligation (EVL)
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06846346

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

AI 简述这是一项II期试验，研究Ivonescimab联合化疗用于晚期胃或胃食管腺癌。

?

适用疾病: Metastatic Esophageal Adenocarcinoma；Advanced Esophageal Adenocarcinoma；Metastatic Gastric Adenocarcinoma
干预: Ivonescimab，FOLFOX regimen，Irinotecan，Paclitaxel
地点: France
申办方: UNICANCER

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06943521 / NCI-2025-04636

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究MT-4561用于多种晚期实体瘤，在美国和日本开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Non-small Cell Lung Cancer (NSCLC)；Esophageal Cancer
干预: MT-4561
地点: United States，Japan
申办方: Tanabe Pharma America, Inc.

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT06962137

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

AI 简述这是一项II期试验，在Belgium研究Zolbetuximab联合紫杉醇和雷莫芦单抗用于CLDN18.2阳性胃食管癌。

?

适用疾病: Gastric Cancer Adenocarcinoma Metastatic；Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
干预: zolbetuximab，Retrospective cohort, no intervention
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07039162

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，研究替雷利珠单抗联合放化疗和手术用于不可切除食管鳞癌，在台湾开展。

?

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)；Locally Advanced Unresectable Esophageal Cancer
干预: Tislelizumab，Paclitaxel，Cisplatin，Radiation Therapy
地点: Taiwan
申办方: Ming-Yu Lien

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07109726 / NCI-2025-06210

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

AI 简述这是一项I/II期试验，研究TER-2013用于AKT/PI3K/PTEN通路改变的实体瘤。

?

适用疾病: Breast Cancer；Endometrial Cancer；Ovarian Cancer
干预: TER-2013，Fulvestrant injection
地点: United States，Puerto Rico
申办方: Terremoto Biosciences Inc.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07152678

Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，在台湾研究纳武利尤单抗联合近距离放疗和放疗用于食管鳞状细胞癌。

?

适用疾病: Esophageal Cancer；Esophageal Squamous Cell Carcinoma
干预: Nivolumab (240 mg)，Brachytherapy
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07189871 / NCI-2026-03797

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究177Lu-BetaBart用于复发/难治性局部晚期不可切除或转移性实体瘤。

?

适用疾病: Castration-Resistant Prostate Cancer (CRPC)；Colorectal Cancer；NSCLC (Non-small Cell Lung Cancer)
干预: 177Lu-BetaBart
地点: United States
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07205731

Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

AI 简述这是一项II期试验，研究Tislelizumab用于不适合化疗的老年晚期食管鳞状细胞癌患者。在法国等地开展。

?

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1
地点: France
申办方: University Hospital, Clermont-Ferrand

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07223424

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

AI 简述这是一项II期试验，研究患者对皮下与静脉注射免疫治疗的偏好。在美国开展。

?

适用疾病: Renal Cell Carcinoma；Non Small Cell Lung Cancer；Melanoma
干预: nivolumab，pembrolizumab
地点: United States
申办方: Diwakar Davar

正在招募 Phase 2 诊断检测手术/操作

ClinicalTrials.gov / NCI NCT07282912 / NCI-2026-03014

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

AI 简述这是一项II期试验，比较标准治疗联合或不联合序贯减瘤干预用于转移性前肠腺癌且ctDNA阴性患者，在美国开展。

?

适用疾病: Foregut Adenocarcinoma；Esophageal Adenocarcinoma；Gastroesophageal Adenocarcinoma
干预: Sequential cytoreductive intervention，Signatera Genome ultra-sensitive ctDNA blood test
地点: United States
申办方: Yale University

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

AI 简述这是一项1/2期试验，研究SL-28用于多种晚期实体瘤（如头颈癌、胰腺癌、肺癌）。在澳大利亚开展。

?

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07488676 / NCI-2026-04341

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

AI 简述这是一项I/II期试验，研究ASP546C用于胃食管癌、胰腺癌或其他实体瘤，在美国和日本开展。

?

适用疾病: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma；Pancreatic Adenocarcinoma；Metastatic Malignant Solid Tumor
干预: ASP546C
地点: United States，Japan
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07546812

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

AI 简述这是一项II期试验，研究Denikitug单药或联合Nivolumab或化疗用于转移性胃、胃食管结合部及食管腺癌（HER2阴性）。

?

适用疾病: HER2-negative；Gastroesophageal Junction；Esophageal Adenocarcinoma
干预: Denikitug，Nivolumab，Ramucirumab，Paclitaxel
地点: Australia
申办方: Gilead Sciences

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07554521

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

AI 简述这是一项II期试验，研究替雷利珠单抗联合化疗用于晚期不可切除胃癌、胃食管腺癌或食管鳞癌的美国少数族裔患者，在美国开展。

?

适用疾病: Advanced Unresectable Gastric Adenocarcinoma；Esophageal Squamous Cell Carcinoma；Advanced Gastroesophageal Adenocarcinoma
干预: Tislelizumab，Capecitabine，5-fluorouracil (5-FU)，Oxaliplatin
地点: United States
申办方: BeOne Medicines

即将招募 Phase 2 生物制剂联合产品药物

ClinicalTrials.gov NCT07059611

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

AI 简述这是一项II期试验，研究瘤内注射RP2联合FLOT方案用于胃食管腺癌，在美国开展。

?

适用疾病: Gastric Adenocarcinoma；Esophageal Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: RP2，5-Fluorouracil，Leucovorin，Oxaliplatin
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

即将招募 Phase 2 其他手术/操作

ClinicalTrials.gov NCT07222657

Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma

AI 简述这是一项II期试验，研究液氮喷雾冷冻治疗用于食管腺癌。在美国开展。

?

适用疾病: Esophageal Adenocarcinoma；Esophageal Cancer
干预: Standard of care chemotherapy，LNSC
地点: United States
申办方: Case Comprehensive Cancer Center

即将招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov NCT07594626

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

AI 简述这是一项I/II期试验，研究PRMT5抑制剂BMS-986504联合培美曲塞用于MTAP缺失的转移性实体瘤。

?

适用疾病: Metastatic Biliary Tract Carcinoma；Metastatic Colon Carcinoma；Metastatic Esophageal Carcinoma
干预: Biospecimen Collection，Computed Tomography，Pemetrexed，PRMT5 Inhibitor BMS-986504
地点: United States
申办方: Northwestern University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07603375

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

AI 简述这是一项II期试验，研究FOLFOX方案化疗联合放疗用于局限性食管腺癌。在美国开展。

?

适用疾病: Esophageal Adenocarcinoma
干预: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
地点: United States
申办方: Duke University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07625930

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

AI 简述这是一项II期试验，研究辛伐他汀联合FLOT方案用于胃食管腺癌。在加拿大等地开展。

?

适用疾病: Gastroesophageal Adenocarcinoma
干预: SOC neoadjuvant FLOT (or FLOT-D) + simvastatin，SOC neoadjuvant FLOT (or FLOT-D)
地点: Canada
申办方: McGill University Health Centre/Research Institute of the McGill University Health Centre

正在招募 Phase 1

NCI NCT03076372 / NCI-2017-01170

A Study Evaluating MM-310 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究MM-310用于多种晚期实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Prostate Adenocarcinoma；Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Merrimack Pharmaceuticals

正在招募 Phase 1

NCI NCT02675946 / NCI-2018-00241

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

AI 简述这是一项I期试验，研究CGX1321单用或联合Pembrolizumab或Encorafenib+Cetuximab用于晚期实体瘤和晚期胃肠道肿瘤。

?

适用疾病: Stage IIIA Esophageal Cancer；Stage IIIB Esophageal Cancer；Stage IIIC Esophageal Cancer
干预: 未列出
地点: United States
申办方: Curegenix Inc.

正在招募 Phase 1

NCI NCT03943004 / NCI-2019-04697

Trial of DFP-14927 in Advanced Solid Tumors

AI 简述这是一项I期试验，研究DFP-14927用于晚期实体瘤。

?

适用疾病: Refractory Malignant Solid Tumor；Refractory Pancreatic Carcinoma；Recurrent Gastroesophageal Junction Adenocarcinoma
干预: 未列出
地点: United States
申办方: Delta-Fly Pharma, Inc.

正在招募 Phase 1

NCI NCT03986606 / NCI-2019-05462

A Study of PSB205 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PSB205用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

正在招募 Phase 1

NCI NCT04511039 / NCI-2020-05678

Trifluridine/Tipiracil in Combination with Talazoparib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

AI 简述这是一项I期试验，研究Trifluridine/Tipiracil联合Talazoparib用于局部晚期或转移性结直肠癌或胃食管癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1

NCI NCT04450732 / NCI-2020-05876

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

AI 简述这是一项I期试验，研究GQ1001用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: GeneQuantum Healthcare (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT04361708 / NCI-2020-13964

gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study

AI 简述这是一项I期试验，研究伊立替康联合5-FU、亚叶酸、奥沙利铂和多西他赛用于胰腺癌或胃食管交界腺癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

正在招募 O

NCI NCT05041153 / NCI-2021-09188

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

AI 简述这是一项早期I期试验，研究Pembrolizumab联合Lenvatinib用于晚期胃食管腺癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT05187182 / NCI-2022-02312

Emavusertib in Combination with Combination Chemotherapy and Immunotherapy with or without Trastuzumab for the Treatment of Advanced Unresectable or Metastatic Gastric or Esophageal Cancer

AI 简述这是一项I期试验，研究CA-4948联合FOLFOX/PD-1抑制剂加或不加Trastuzumab用于晚期胃癌和食管癌。在美国开展。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

正在招募 Phase 1

NCI NCT05238922 / NCI-2022-03370

Study of INCB123667 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究INCB123667用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Incyte Corporation

正在招募 Phase 1

NCI NCT05274048 / NCI-2022-05652

Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer

AI 简述这是一项I期试验，研究Neratinib联合Fam-Trastuzumab Deruxtecan用于晚期胃食管癌。

?

适用疾病: Unresectable Esophageal Carcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1

NCI NCT05365581 / NCI-2022-09348

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

AI 简述这是一项I期试验，研究ASP2138联合其他药物用于胃癌、胃食管交界处癌或胰腺癌，在美国、中国等地开展。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1

NCI NCT06131840 / NCI-2023-10543

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

AI 简述这是一项I期试验，研究SGN-CEACAM5C用于晚期实体瘤，在美国、加拿大、中国、法国等地开展。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 1

NCI NCT05954312 / NCI-2024-00249

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究VVD-130037用于多种晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Vividion Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06108050 / NCI-2024-01130

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究JZP898单药或联合Pembrolizumab用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Jazz Pharmaceuticals

正在招募 Phase 1

NCI NCT06240728 / NCI-2024-01335

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

AI 简述这是一项1期试验，研究NPX887用于表达B7-H7的实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

正在招募 Phase 1

NCI NCT05957536 / NCI-2024-01363

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

AI 简述这是一项I期试验，研究D3L-001单药用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: D3 Bio (Wuxi) Co., Ltd

正在招募 Phase 1

NCI NCT06364410 / NCI-2024-02982

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients with Stomach or Other Solid Tumors

AI 简述这是一项I期试验，研究Trastuzumab Deruxtecan联合Azenosertib用于胃癌或其他实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Texas MD Anderson Cancer Center LAO

正在招募 Phase 1

NCI NCT06244485 / NCI-2024-04787

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究Valemetostat Tosylate联合DXd ADC用于实体瘤患者。

?

适用疾病: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1

NCI NCT06384352 / NCI-2024-07039

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究YL211用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06475937 / NCI-2024-09195

A Study of DM001 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究DM001用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06529822 / NCI-2025-00334

A Personalized Cancer Vaccine for the Treatment of Muscle-Invasive Bladder Cancer, Gastroesophageal Cancer, Melanoma, and Non-small Cell Lung Cancer in Patients with Molecular Residual Disease

AI 简述这是一项1期试验，研究个性化癌症疫苗联合Poly ICLC用于实体瘤分子残留病灶阳性患者，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

正在招募 Phase 1

NCI NCT06586957 / NCI-2025-00731

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究NKT3964用于晚期/转移性实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: NiKang Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06752681 / NCI-2025-03245

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究DAY301用于局部晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；FIGO Stage III Ovarian Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Day One Biopharmaceuticals, Inc.

正在招募 Phase 1

NCI NCT06657144 / NCI-2025-04098

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究CHS-114（Tagmokitug）联合Toripalimab等用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Coherus Oncology, Inc.

正在招募 Phase 1

NCI NCT06756035 / NCI-2025-04725

CT-95 in Advanced Cancers Associated With Mesothelin Expression

AI 简述这是一项I期试验，研究CT-95用于间皮素表达的晚期实体瘤，包括卵巢癌、间皮瘤和胰腺癌。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Context Therapeutics Inc.

正在招募 Phase 1

NCI NCT05733689 / NCI-2025-04867

A Response-Guided Neoadjuvant Treatment Approach for Treating Stage Ib-III Stomach or Gastroesophageal Junction Cancer, RANT-GC Trial

AI 简述这是一项1期试验，研究响应指导的新辅助治疗用于IB-III期胃癌或胃食管结合部癌。

?

适用疾病: Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: UC Irvine Health/Chao Family Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT07015697 / NCI-2025-05451

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

AI 简述这是一项I期试验，研究皮下注射Trastuzumab Deruxtecan用于转移性实体瘤患者。

?

适用疾病: Metastatic Malignant Solid Tumor；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募阶段未标明

NCI NCT07132918 / NCI-2025-06177

The Cardiac Radiation Therapy Sparing for Thoracic Cancers, HEARTS Trial

AI 简述这是一项II期试验，研究MRgART或LINAC用于胸部肿瘤，包括非小细胞肺癌、食管癌等，在美国开展。

?

适用疾病: Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 1

NCI NCT07030712 / NCI-2025-06272

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

AI 简述这是一项1期试验，研究MK-8294用于晚期实体瘤，包括食管鳞癌和头颈鳞癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1

NCI NCT06999187 / NCI-2025-07429

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

AI 简述这是一项I期试验，研究DR-0202用于晚期复发难治性癌，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Dren Bio

正在招募 Phase 1

NCI NCT06959706 / NCI-2025-08169

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究TGW101用于晚期实体瘤，包括转移性及局部晚期实体瘤等，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Tagworks Pharmaceuticals BV

正在招募 Phase 1

NCI NCT06789172 / NCI-2025-08170

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

AI 简述这是一项I期试验，研究OKN4395联合帕博利珠单抗用于实体瘤，包括肉瘤、头颈癌、非小细胞肺癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage III Lip and Oral Cavity Cancer；Stage IV Lip and Oral Cavity Cancer
干预: 未列出
地点: United States
申办方: Epkin

正在招募 Phase 1

NCI NCT07197671 / NCI-2025-08356

Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer

AI 简述这是一项I期试验，研究Y-NM600联合免疫检查点抑制剂用于转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 1

NCI NCT06809114 / NCI-2026-00164

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AT03-65用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Axcynsis Therapeutics Pte Ltd

正在招募 Phase 1

NCI NCT07218003 / NCI-2026-00632

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

AI 简述这是一项I期试验，研究RNDO-564单药或联合Pembrolizumab用于Nectin-4阳性实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Rondo Therapeutics

正在招募 Phase 1

NCI NCT05872295 / NCI-2026-00679

IKS014 in Advanced Solid Tumors That Express HER2

AI 简述这是一项I期试验，研究IKS014用于HER2阳性晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Iksuda Therapeutics Ltd.

正在招募 Phase 1

NCI NCT05458219 / NCI-2026-02256

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究IBI343用于局部晚期不可切除或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Innovent Biologics (Suzhou) Co. Ltd.

正在招募 Phase 1

NCI NCT07532902 / NCI-2026-03007

A Study of BMS-986504 with Standard-of-Care Therapy for the Treatment of Patients with Advanced, Metastatic or Unresectable Solid Tumor Cancer with MTAP Loss

AI 简述这是一项I期试验，研究BMS-986504联合标准疗法用于MTAP缺失的晚期实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Stage II Esophageal Squamous Cell Cancer；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1

NCI NCT05841563 / NCI-2026-03026

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

AI 简述这是一项I期试验，在美国开展，研究PM54用于晚期实体瘤患者。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: PharmaMar SA

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT03222635

Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma

AI 简述这是一项观察性研究，通过内镜随访监测食管黏膜下及高危黏膜腺癌患者。

?

适用疾病: Submucosal Esophageal Adenocarcinoma；Barrett Esophagus；High-risk Mucosal Esophageal Adenocarcinoma
干预: Endoscopic follow-up
地点: Australia，Belgium，Germany，Netherlands 等 2 个
申办方: Amsterdam UMC

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT03740256 / NCI-2021-01066

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

AI 简述这是一项I期试验，研究CAdVEC用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Bladder Cancer；Head and Neck Squamous Cell Carcinoma；Cancer of the Salivary Gland
干预: CAdVEC
地点: United States
申办方: Baylor College of Medicine

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT04221893 / NCI-2019-08355

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

AI 简述这是一项试验，研究放射治疗用于转移性胃肠癌，包括食管癌、胃癌等。

?

适用疾病: Stage IV Esophageal Adenocarcinoma；Stage IV Esophageal Squamous Cell Carcinoma；Stage IV Gastric Cancer
干预: Radiation Therapy (RT)
地点: United States
申办方: University of California, San Francisco

正在招募阶段未标明器械手术/操作

ClinicalTrials.gov NCT04306458

RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).

AI 简述这是一项随机对照试验，在德国比较机器人辅助与微创食管切除术用于可切除食管腺癌。

?

适用疾病: Esophageal Adenocarcinoma
干预: Minimally invasive esophagectomy，daVinci Xi system
地点: Germany
申办方: University Medical Center Mainz

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04389632 / NCI-2020-03931

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Sigvotatug Vedotin用于晚期实体瘤，在美国、法国、韩国、西班牙等地开展。

?

适用疾病: Carcinoma, Non-Small Cell Lung；Squamous Cell Carcinoma of Head and Neck；HER2 Negative Breast Neoplasms
干预: sigvotatug vedotin，pembrolizumab，cisplatin，carboplatin
地点: United States，France，South Korea，Spain 等 3 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募阶段未标明药物放疗

ClinicalTrials.gov NCT04481256

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

AI 简述这是一项试验，研究Bintrafusp alfa联合放化疗用于食管鳞癌，在荷兰开展。

?

适用疾病: Carcinoma, Squamous Cell；Oesophageal Cancer
干预: External beam radiotherapy，Bintrafusp alfa，Paclitaxel，Carboplatin
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 1 药物其他放疗

ClinicalTrials.gov / NCI NCT04615013 / NCI-2020-05329

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

AI 简述这是一项1期试验，研究NBTXR3联合化疗和放疗用于食管癌，在美国开展。

?

适用疾病: Cervical Esophagus Adenocarcinoma；Clinical Stage II Esophageal Adenocarcinoma AJCC v8；Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
干预: Capecitabine，Carboplatin，Docetaxel，Fluorouracil
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04999761

AB122 Platform Study

AI 简述这是一项I期试验，研究AB122联合TAS-116、TAS-120、TAS-115用于晚期或转移性实体瘤，在日本开展。

?

适用疾病: Advanced or Metastatic Solid Tumor；Pancreatic Ductal Adenocarcinoma；Colorectal Cancer
干预: AB122，AB122，TAS-116，AB122
地点: Japan
申办方: Taiho Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05005403 / NCI-2025-01100

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AI 简述这是一项I期试验，研究Azirkitug单药或联合其他药物用于非小细胞肺癌等实体瘤，在美国、加拿大等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Micro Satellite Stable Colorectal Cancer
干预: Azirkitug，Budigalimab，Bevacizumab，Telisotuzumab Adizutecan
地点: United States，Canada，Israel，Japan 等 2 个
申办方: AbbVie

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05370144

A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项试验，研究低分次放疗联合新辅助放化疗用于食管癌和胃食管交界处腺癌，在加拿大开展。

?

适用疾病: Esophageal Cancer
干预: Hypofractionated radiotherapy
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项1期试验，研究Enzelkitug单药或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；NSCLC；HNSCC
干预: Enzelkitug，Atezolizumab，Pembrolizumab
地点: United States，Australia，Belgium，Canada 等 6 个
申办方: Genentech, Inc.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT05753748

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

AI 简述这是一项在美国的研究，比较内镜治疗与监测用于Barrett食管伴低度不典型增生。

?

适用疾病: Barretts Esophagus With Dysplasia；Barrett Esophagus；Esophageal Adenocarcinoma
干预: Endoscopic Eradication Therapy
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05983432 / NCI-2023-10398

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

AI 简述这是一项I期试验，研究BL-B01D1用于转移性或不可切除非小细胞肺癌及其他实体瘤，在美国、法国等地开展。

?

适用疾病: Non Small Cell Lung Cancer；Lung Cancer；Breast Cancer
干预: BL-B01D1
地点: United States，France，Italy，Japan 等 1 个
申办方: SystImmune Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06266299 / NCI-2024-08649

A Study of KK2269 in Adult Participants With Solid Tumors

AI 简述这是一项I期试验，研究KK2269用于晚期实体瘤，在美国和日本开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Gastric Adenocarcinoma
干预: KK2269，Docetaxel
地点: United States，Japan
申办方: Kyowa Kirin Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06545331 / NCI-2024-09409

Study of XB010 in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究XB010联合Pembrolizumab用于多种晚期实体瘤。在美国、英国等地开展。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；Esophageal Squamous Cell Cancer；Head and Neck Squamous Cell Cancer
干预: XB010，Pembrolizumab
地点: United States，United Kingdom
申办方: Exelixis

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06623396 / NCI-2024-08421

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

AI 简述这是一项I期试验，在美国研究靶向间皮素的CAR-T细胞疗法用于食管胃结合部癌。

?

适用疾病: Mesothelin Positive；Mesothelin-Expressing Tumors；Esophageal Adenocarcinoma
干预: M28z1XXPD1DNR CAR
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov / NCI NCT06824363 / NCI-2025-08761

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

AI 简述这是一项早期I期试验，研究Tremelimumab联合Durvalumab用于胃食管腺癌伴ARID1a突变，在美国开展。

?

适用疾病: Solid Tumor, Adult；Malignant Solid Tumor；Stomach Adenocarcinoma
干预: Tremelimumab，Durvalumab
地点: United States
申办方: University of California, Irvine

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDOV-Immune用于晚期实体瘤，包括结直肠癌、胰腺癌等。在美国和澳大利亚开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07001592

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

AI 简述这是一项I期试验，在美国研究瘤内注射vvDD-hIL2-2-RG-1用于转移性胃肠和腹膜肿瘤。

?

适用疾病: Gastric Neoplasms；Esophageal Cancer；Liver Cancer
干预: vvDD-hIL-2-RG-1
地点: United States
申办方: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07021066 / NCI-2025-07108

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究BL-M05D1用于晚期实体瘤，在美国开展。

?

适用疾病: Gastric Adenocarcinoma；Advanced Pancreatic Ductal Adenocarcinoma；Esophageal Adenocarcinoma
干预: BL-M05D1
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07059299

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

AI 简述这是一项I期试验，研究替雷利珠单抗联合FLOT方案用于可切除食管胃腺癌，在德国开展。

?

适用疾病: Esophagogastric Junction Adenocarcinoma；Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: Tislelizumab，FLOT Chemotherapy
地点: Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07085091 / NCI-2025-05711

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

AI 简述这是一项I期试验，在美国开展，首次研究ALX2004用于晚期或转移性实体瘤。

?

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)；HNSCC；CRC (Colorectal Cancer)
干预: ALX2004
地点: United States
申办方: ALX Oncology Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07090499 / NCI-2025-07625

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PF-08046876用于晚期实体瘤，在美国、加拿大等地开展。

?

适用疾病: Advanced/Metastatic Solid Tumors；Bladder Cancer；Urothelial Carcinoma
干预: PF-08046876
地点: United States，Canada，Puerto Rico，Spain 等 1 个
申办方: Pfizer

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07182149 / NCI-2026-01556

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究NRM-823用于晚期难治性实体瘤。

?

适用疾病: HNSCC；ESCC；Esophageal Adenocarcinoma
干预: NRM-823
地点: United States
申办方: Normunity AccelCo, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07217171 / NCI-2026-02116

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

AI 简述这是一项1期试验，研究EVOLVE104用于晚期尿路上皮癌和鳞状细胞癌。

?

适用疾病: Bladder Cancer；Squamous Cell Carcinoma of the Lung；Esophageal Squamous Cell Carcinoma
干预: EVOLVE104
地点: United States
申办方: EvolveImmune United, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07227168 / NCI-2026-01753

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

AI 简述这是一项I期试验，研究STRO-004联合Pembrolizumab用于难治性/复发性转移性实体瘤，在美国开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma HNSCC；Non-Small Cell Lung Cancer NSCLC；Esophageal Cancer
干预: STRO-004，Pembrolizumab
地点: United States
申办方: Sutro Biopharma, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07277413 / NCI-2026-03872

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDE892单药或联合IDE397用于MTAP缺失的晚期实体瘤，在美国开展。

?

适用疾病: NSCLC Adenocarcinoma；Gastroesophageal Cancer (GC)；Gastric Adenocarcinoma
干预: IDE892，IDE397
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07284186

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究PLX-61639用于局部晚期或转移性实体瘤，包括食管鳞癌、胃腺癌等。

?

适用疾病: Esophageal Squamous Cell Carcinoma；Gastric Adenocarcinoma；Gastric Squamous Cell Carcinoma
干预: PLX-61639
地点: United States
申办方: Plexium, Inc.

正在招募 Phase 1 放疗

ClinicalTrials.gov NCT07359443

Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma

AI 简述这是一项I期试验，研究适应性MRI引导放疗联合化疗用于食管腺癌，在荷兰开展。

?

适用疾病: Esophageal Adenocarcinoma；Esophageal Adenocarcinoma (EAC)；Adenocarcinoma - Gastroesophageal Junction (GEJ)
干预: MRI guided radiotherapy
地点: Netherlands
申办方: UMC Utrecht

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07481357

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I/IIa期试验，研究DA-3501用于晚期胃/胃食管结合部腺癌和胰腺癌。

?

适用疾病: Gastric (Stomach) Cancer；GastroEsophageal Cancer；Pancreatic Ductal Adenocarcinoma (mPDAC)
干预: DA-3501
地点: South Korea
申办方: Dong-A ST Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07503808 / NCI-2026-03006

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

AI 简述这是一项I期试验，研究IDE034用于局部晚期或转移性实体瘤成人患者。

?

适用疾病: Esophageal Squamous Cell Carcinoma；High Grade Serous Ovarian Cancer；Head and Neck Squamous Cell Carcinoma
干预: IDE034
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07544589 / NCI-2026-03246

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

AI 简述这是一项I期试验，在美国评估DISP-10用于晚期胃肠道癌症。

?

适用疾病: Colorectal Cancer；Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: DISP-10
地点: United States
申办方: Dispatch Biotherapeutics

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05713838

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

AI 简述这是一项II期试验，研究Durvalumab联合化疗放疗用于早期食管腺癌的器官保留治疗。

?

适用疾病: Esophagus Adenocarcinoma
干预: Durvalumab，FLOT，mFOLFOX-6，Radiotherapy
地点: Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06764355

Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，在台湾研究新辅助免疫化疗和放化疗后手术用于晚期食管鳞癌。

?

适用疾病: ESCC；Total Neoadjuvant Treatment；Pathological Complete Response
干预: Tislelizumab，Paclitaxel，Cisplatin，Chemoradiotherapy
地点: Taiwan
申办方: National Taiwan University Hospital

暂时不招募 Phase 2, Phase 3

NCI NCT03604991 / NCI-2018-01575

Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

AI 简述这是一项II/III期试验，研究Nivolumab联合Ipilimumab用于可切除食管或胃食管交界处腺癌。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IVA Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: ECOG-ACRIN Cancer Research Group

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06501664

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

AI 简述这是一项III期试验，比较脂质体伊立替康联合5-FU与伊立替康联合5-FU用于食管癌二线治疗。

?

适用疾病: Esophageal Cancer
干预: liposomal irinotecan，5-FU，LV，Irinotecan
地点: 未列出
申办方: Rui-hua Xu, MD, PhD

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07251062

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

AI 简述这是一项II/III期试验，研究SYS6010联合Enlonstobart和化疗用于一线食管鳞状细胞癌。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)，Investigator's choice of SOC，SYS6010+SG001
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07621601

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

AI 简述这是一项III期试验，研究HS-20093用于既往治疗过的晚期食管鳞状细胞癌。

?

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: HS-20093 for Injection，Irinotecan; Paclitaxel; Docetaxel
地点: 未列出
申办方: Hansoh BioMedical R&D Company

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07417735

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

AI 简述这是一项III期试验，比较SYS6010与化疗用于局部晚期或转移性/复发性食管鳞癌。

?

适用疾病: Locally Advanced/Metastatic/Recurrent ESCC
干预: SYS6010，Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

暂时不招募 Phase 1

NCI NCT02366819 / NCI-2014-02574

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of gFOLFIRINOX in Treating Patients with Locally Advanced Gastroesophageal or Stomach Cancer

AI 简述这是一项I期试验，研究基因指导下的伊立替康剂量调整用于局部晚期食管胃结合部腺癌或胃癌。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

暂时不招募 Phase 2

NCI NCT03776487 / NCI-2018-02344

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients with Resectable Gastric Cancer

AI 简述这是一项II期试验，研究Nivolumab、Ipilimumab和放化疗用于可切除胃癌。

?

适用疾病: Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT05400122 / NCI-2022-07858

Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers

AI 简述这是一项I期试验，研究通用供者NK细胞联合Aldesleukin和Vactosertib用于局部晚期或转移性结直肠癌、胃癌、食管癌及血液肿瘤。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT05958199 / NCI-2023-06569

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

AI 简述这是一项I期试验，研究NPX267用于表达HHLA2/B7-H7的实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

暂时不招募 Phase 2

NCI NCT06044311 / NCI-2023-10645

Vactosertib for the Treatment of Patients who are Undergoing Standard of Care Chemoradiation for Locally Advanced Esophageal Cancer

AI 简述这是一项II期试验，研究Vactosertib联合标准放化疗用于局部晚期食管癌。在美国开展。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

即将招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT06748872

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

AI 简述这是一项I期试验，研究MDG1015用于上皮性卵巢癌、胃食管交界癌、软组织肉瘤等，在美国开展。

?

适用疾病: Epithelial Ovarian Cancer；Gastro-esophageal Junction Cancer；Soft Tissue Sarcoma (STS)
干预: Lymphodepletion，TCR-T cells (MDG1015)
地点: United States
申办方: Medigene AG

即将招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov NCT07594548

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

AI 简述这是一项I期试验，研究Futibatinib联合紫杉醇和雷莫西尤单抗用于晚期胃癌、食管胃结合部癌或食管腺癌。

?

适用疾病: Clinical Stage II Esophageal Adenocarcinoma AJCC v8；Clinical Stage III Esophageal Adenocarcinoma AJCC v8；Clinical Stage III Gastric Cancer AJCC v8
干预: Biospecimen Collection，Computed Tomography，Futibatinib，Magnetic Resonance Imaging
地点: United States
申办方: Northwestern University

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05628610

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

AI 简述这是一项II期试验，研究Tislelizumab联合化疗或放疗用于晚期或复发转移性老年食管癌。

?

适用疾病: Esophageal Cancer
干预: Tislelizumab，Radiation，Paclitaxel，Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05996484

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

AI 简述这是一项II期试验，研究安罗替尼联合Toripalimab和化疗用于可切除食管癌的新辅助治疗。

?

适用疾病: Esophageal Carcinoma；Neoadjuvant Therapy
干预: Toripalimab，Anlotinib hydrochloride，Albumin paclitaxel，Cisplatin
地点: 未列出
申办方: Nanfang Hospital, Southern Medical University

即将招募 Phase 4 药物

ClinicalTrials.gov NCT06388135

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

AI 简述这是一项IV期试验，研究Serplulimab联合白蛋白紫杉醇和顺铂用于可切除食管鳞癌的新辅助治疗。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Serplulimab Combined With Nab-paclitaxel and Cisplatin，nab-paclitaxel，Cisplatin
地点: 未列出
申办方: Yang Jianjun, PhD

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06468644

Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，研究不同放疗剂量联合Sintilimab用于局部晚期食管鳞癌。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: chemoradiotherapy （CRT）+sintilimab 1，CRT+sintilimab 2
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06468670

Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，研究短程放疗联合Sintilimab用于食管鳞癌的新辅助治疗。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: sintilimab，programmed death 1 monoclonal antibody
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06491134

Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma

AI 简述这是一项I期试验，研究脂质体伊立替康联合顺铂和同步放疗用于局部晚期食管鳞癌。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Liposomal Irinotecan Hydrochloride
地点: 未列出
申办方: Hebei Medical University Fourth Hospital

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06746961

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

AI 简述这是一项I/II期试验，研究QL1706联合Lenvatinib用于转移性食管鳞癌的二线治疗。

?

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)，Lenvatinib
地点: 未列出
申办方: The First Affiliated Hospital of Zhengzhou University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06852456

QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，研究QL1706联合新辅助化疗用于局部晚期可切除食管鳞癌。

?

适用疾病: Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
干预: Iparomlimab and Tuvonralimab (QL1706)Injection，Paclitaxel，Cisplatin
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06979986

SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma

AI 简述这是一项试验，比较内镜切除后淋巴结清扫与不清扫用于T1a期食管鳞癌。

?

适用疾病: Esophageal Cancer
干预: Endoscopic Submucosal Dissection with Systematically mediastinal Lymph Node Dissection，Endoscopic Submucosal Dissection without SLND
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07126561

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

AI 简述这是一项II期试验，研究Trastuzumab Deruxtecan用于HER2阳性新诊断转移性食管、胃、胃食管结合部癌。

?

适用疾病: HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
干预: Trastuzumab Deruxtecan
地点: 未列出
申办方: University of Chicago

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07128693

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，研究Sacituzumab Tirumotecan联合替雷利珠单抗或安罗替尼用于食管鳞癌。

?

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Sacituzumab Tirumotecan in combination with tislelizumab，Sacituzumab Tirumotecan in combination with anlotinib
地点: 未列出
申办方: The First Affiliated Hospital of Zhengzhou University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07490002

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

AI 简述这是一项II期试验，研究Iparomlimab和Tuvonralimab联合仑伐替尼和化疗用于可切除食管鳞癌的新辅助治疗。

?

适用疾病: Esophageal Squamous Carcinoma
干预: Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
地点: 未列出
申办方: Changhai Hospital

即将招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT06836778

Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices

AI 简述这是一项试验，比较卡维地洛单药与联合内镜静脉曲张结扎术用于肝癌伴高危食管静脉曲张的首次出血预防，在印度开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Carvedilol Tablets，Endoscopic Variceal Ligation
地点: India
申办方: Institute of Liver and Biliary Sciences, India

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07507968

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

AI 简述这是一项II期试验，在Germany、Spain研究FLOT化疗联合Durvalumab及术后Durvalumab用于可切除胃食管腺癌。

?

适用疾病: Esophagogastric Adenocarcinoma
干预: Durvalumab
地点: Germany，Spain
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07643727

Development of Fluorescent Lectin Tracers With Dedicated Technology for in Vivo Detection of Esophageal Dysplasia in Barrett Patients

AI 简述这是一项I期试验，开发荧光凝集素示踪剂WGA-800CW用于巴雷特食管发育不良的体内检测，在荷兰开展。

?

适用疾病: Barrett's Esophagus With or Without Dysplasia；Barrett Esophagus Adenocarcinoma
干预: WGA-800CW
地点: Netherlands
申办方: University Medical Center Groningen

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06692270

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

AI 简述这是一项II期试验，研究替雷利珠单抗单药新辅助治疗用于可切除食管鳞癌。

?

适用疾病: Esophagus Cancer
干预: Tislelizumab
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07019181

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

AI 简述这是一项II期试验，研究替雷利珠单抗联合化疗用于食管鳞癌的围手术期治疗。

?

适用疾病: Esophagus Cancer
干预: Tislelizumab，albumin-bound paclitaxel，Nedaplatin
地点: 未列出
申办方: The First Affiliated Hospital of Xiamen University

即将招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT07046221

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

AI 简述这是一项II期试验，研究替雷利珠单抗联合化疗用于可切除食管鳞癌，之后进行放化疗或手术。

?

适用疾病: Esophagus Cancer
干预: Tislelizumab，Albumin-Bound Paclitaxel，cis-platinum，Surgery
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT07680569

Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

AI 简述这是一项I/II期试验，研究HCB101联合多种药物用于晚期胃癌或胃食管交界腺癌。

?

适用疾病: GC/GEJC
干预: Zolbetuximab，Oxaliplatin + 5-Fluorouracil/Leucovorin，CAPOX (oxaliplatin/capecitabine)
地点: 未列出
申办方: Kaohsiung Medical University Chung-Ho Memorial Hospital

术语	中文意思	对找临床试验有什么用
食管鳞癌 / ESCC	中国较常见的食管癌病理类型。	海外试验常区分 squamous cell carcinoma 和 adenocarcinoma。
食管腺癌 / Esophageal adenocarcinoma	另一类食管癌病理类型，在欧美较常见。	如果病理是腺癌，搜索时要加 adenocarcinoma。
PD-L1	和免疫治疗相关的生物标志物。	免疫治疗试验可能要求 PD-L1 表达或按表达分层。
Chemoradiation	同步或序贯放化疗，常见于局部晚期治疗路径。	试验可能限定既往是否接受过放化疗。
转移性食管癌 / metastatic esophageal cancer	癌症已扩散到远处器官或淋巴结。	很多系统治疗试验会限定 metastatic 或 advanced 患者。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

食管癌

当前同步到的治疗类试验